《大行報告》花旗對蘋果(AAPL.US)開啓90日上行催化觀察
花旗發表研究報告指,蘋果(AAPL.US)將於9月份發佈新iPhone 15系列產品,對其開展90日上行催化觀察。
該行解釋,蘋果自2016年以來,在每年6月份發佈財報及9月份發佈新產品期間,7年間股價平均跑贏納斯達克五次,並全部七次跑贏標準普爾500指數。
花旗對蘋果給予「買入」評級,表示投資者對宏觀經濟前景及消費者開支的擔憂合理,但相信蘋果在產品活躍安裝基礎及用戶訂閱的增長具韌性,將推動未來幾年產品需求,目標價爲240美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.